The mRNA therapeutics market would grow at a CAGR of 13.03% over the predicted time frame. The market is expected to increase in value from US$ 48.1 Bn in 2022 to US$ 128.14 Bn in 2030.
The on mRNA therapeutics Market, which provides a business strategy, research & development activities, concise outline of the market valuation, valuable insights pertaining to market share, size, supply chain analysis, competitive landscape and regional proliferation of this industry.
Download Free Sample@ https://www.precedenceresearch.com/sample/2118
Report Scope of the mRNA therapeutics Market
| Report Coverage | Details |
| Market Size in 2022 |
USD 48.1 Billion |
| Market Size by 2030 |
USD 128.14 Billion |
| Growth Rate from 2022 to 2030 | CAGR of 13.03% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Application, Type, End User, and Geography |
A recent report provides crucial insights along with application based and forecast information in the Global MRNA therapeutics Market. The report provides a comprehensive analysis of key factors that are expected to drive the growth of this market. This study also provides a detailed overview of the opportunities along with the current trends observed in the MRNA therapeutics market.
A quantitative analysis of the industry is compiled for a period of 10 years in order to assist players to grow in the market. Insights on specific revenue figures generated are also given in the report, along with projected revenue at the end of the forecast period.
Companies and Manufacturers Covered
The study covers key players operating in the market along with prime schemes and strategies implemented by each player to hold high positions in the industry. Such a tough vendor landscape provides a competitive outlook of the industry, consequently existing as a key insight. These insights were thoroughly analysed and prime business strategies and products that offer high revenue generation capacities were identified. Key players of the global MRNA therapeutics market are included as given below:
MRNA therapeutics Market Key Players
- Alnylam Pharmaceuticals
- Arcturus Therapeutics
- Argos Therapeutics Inc.
- AstraZeneca plc.
- BioNTech SE
- CRISPR Therapeutics AG
- Curevac AG
- Etherna Immunotherapies
- Ethris GMBH
- GSK plc.
- IN-CELL-ART
- Ionis Pharmaceuticals, Inc
- Moderna Therapeutics
- Nutcracker
- Pfizer Inc.
- Sangamo Therapeutics, Inc.
- Sanofi AG
- Sarepta Therapeutics
- Tiba Biotech
- Translate Bio, Inc.
Market Segments
By Application
- Rare Genetic Diseases
- Oncology
- Respiratory Diseases
- Infectious Diseases
- Others
By Type
- Prophylactic Vaccines
- Therapeutic Vaccines
- Therapeutic Drugs
By End User
- Hospitals & Clinics
- Research Organizations
- Other
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa (MEA)
Report Objectives
- To define, describe, and forecast the global mRNA therapeutics market based on product, and region
- To provide detailed information regarding the major factors influencing the growth of the market (drivers, opportunities, and industry-specific challenges)
- To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the total market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of market segments with respect to four main regions—North America, Europe, Asia Pacific and the Rest of the World (RoW)2
- To strategically profile key players and comprehensively analyze their product portfolios, market shares, and core competencies3
- To track and analyze competitive developments such as acquisitions, expansions, new product launches, and partnerships in the mRNA therapeutics market
Table of Content
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on MRNA Therapeutics Market
5.1. COVID-19 Landscape: MRNA Therapeutics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global MRNA Therapeutics Market, By Application
8.1. MRNA Therapeutics Market, by Application, 2022-2030
8.1.1 Rare Genetic Diseases
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Oncology
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Respiratory Diseases
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Infectious Diseases
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. Others
8.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global MRNA Therapeutics Market, By Type
9.1. MRNA Therapeutics Market, by Type, 2022-2030
9.1.1. Prophylactic Vaccines
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Therapeutic Vaccines
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Therapeutic Drugs
9.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global MRNA Therapeutics Market, By End User
10.1. MRNA Therapeutics Market, by End User, 2022-2030
10.1.1. Hospitals & Clinics
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Research Organizations
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Other
10.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global MRNA Therapeutics Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Application (2017-2030)
11.1.2. Market Revenue and Forecast, by Type (2017-2030)
11.1.3. Market Revenue and Forecast, by End User (2017-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Application (2017-2030)
11.1.4.2. Market Revenue and Forecast, by Type (2017-2030)
11.1.4.3. Market Revenue and Forecast, by End User (2017-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Application (2017-2030)
11.1.5.2. Market Revenue and Forecast, by Type (2017-2030)
11.1.5.3. Market Revenue and Forecast, by End User (2017-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Application (2017-2030)
11.2.2. Market Revenue and Forecast, by Type (2017-2030)
11.2.3. Market Revenue and Forecast, by End User (2017-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Application (2017-2030)
11.2.4.2. Market Revenue and Forecast, by Type (2017-2030)
11.2.4.3. Market Revenue and Forecast, by End User (2017-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Application (2017-2030)
11.2.5.2. Market Revenue and Forecast, by Type (2017-2030)
11.2.5.3. Market Revenue and Forecast, by End User (2017-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Application (2017-2030)
11.2.6.2. Market Revenue and Forecast, by Type (2017-2030)
11.2.6.3. Market Revenue and Forecast, by End User (2017-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Application (2017-2030)
11.2.7.2. Market Revenue and Forecast, by Type (2017-2030)
11.2.7.3. Market Revenue and Forecast, by End User (2017-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Application (2017-2030)
11.3.2. Market Revenue and Forecast, by Type (2017-2030)
11.3.3. Market Revenue and Forecast, by End User (2017-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Application (2017-2030)
11.3.4.2. Market Revenue and Forecast, by Type (2017-2030)
11.3.4.3. Market Revenue and Forecast, by End User (2017-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Application (2017-2030)
11.3.5.2. Market Revenue and Forecast, by Type (2017-2030)
11.3.5.3. Market Revenue and Forecast, by End User (2017-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Application (2017-2030)
11.3.6.2. Market Revenue and Forecast, by Type (2017-2030)
11.3.6.3. Market Revenue and Forecast, by End User (2017-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Application (2017-2030)
11.3.7.2. Market Revenue and Forecast, by Type (2017-2030)
11.3.7.3. Market Revenue and Forecast, by End User (2017-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Application (2017-2030)
11.4.2. Market Revenue and Forecast, by Type (2017-2030)
11.4.3. Market Revenue and Forecast, by End User (2017-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Application (2017-2030)
11.4.4.2. Market Revenue and Forecast, by Type (2017-2030)
11.4.4.3. Market Revenue and Forecast, by End User (2017-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Application (2017-2030)
11.4.5.2. Market Revenue and Forecast, by Type (2017-2030)
11.4.5.3. Market Revenue and Forecast, by End User (2017-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Application (2017-2030)
11.4.6.2. Market Revenue and Forecast, by Type (2017-2030)
11.4.6.3. Market Revenue and Forecast, by End User (2017-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Application (2017-2030)
11.4.7.2. Market Revenue and Forecast, by Type (2017-2030)
11.4.7.3. Market Revenue and Forecast, by End User (2017-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Application (2017-2030)
11.5.2. Market Revenue and Forecast, by Type (2017-2030)
11.5.3. Market Revenue and Forecast, by End User (2017-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Application (2017-2030)
11.5.4.2. Market Revenue and Forecast, by Type (2017-2030)
11.5.4.3. Market Revenue and Forecast, by End User (2017-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Application (2017-2030)
11.5.5.2. Market Revenue and Forecast, by Type (2017-2030)
11.5.5.3. Market Revenue and Forecast, by End User (2017-2030)
Chapter 12. Company Profiles
12.1. Alnylam Pharmaceuticals
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Arcturus Therapeutics
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Argos Therapeutics Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. AstraZeneca plc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. BioNTech SE
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. CRISPR Therapeutics AG
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Curevac AG
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Etherna Immunotherapies
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Ethris GMBH
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. GSK plc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
Blog: https://www.pharma-geek.com
0 Comments